Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Zeitschrift für Rheumatologie
Erschienen in: Zeitschrift für Rheumatologie 1/2019

01.12.2019 | Spondyloarthritiden | Leitlinien

Langfassung zur S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen, Update 2019

Evidenzbasierte Leitlinie der Deutschen Gesellschaft für Rheumatologie (DGRh) und der beteiligten medizinisch-wissenschaftlichen Fachgesellschaften und weiterer Organisationen*

verfasst von: PD Dr. med. U. Kiltz, Prof. Dr. med. J. Braun, Prof. Dr. med. A. Becker, Prof. Dr. med. J.-F. Chenot, PD Dr. med. M. Dreimann, L. Hammel, Prof. Dr. med. A. Heiligenhaus, PD Dr. med. K.‑G. Hermann, Prof. Dr. med. Dipl. Phys. R. Klett, PD Dr. med. D. Krause, Prof. Dr. med. K.‑F. Kreitner, Prof. Dr. med. U. Lange, A. Lauterbach, Prof. Dr. med. W. Mau, Prof. Dr. med. R. Mössner, Dr. med. U. Oberschelp, Dr. med. S. Philipp, Prof. Dr. med. U. Pleyer, Prof. Dr. med. M. Rudwaleit, Dr. med. E. Schneider, Prof. Dr. med. T. L. Schulte, Prof. Dr. med. em. J. Sieper, Prof. Dr. med. A. Stallmach, Prof. Dr. med. B. Swoboda, Prof. Dr. med. M. Winking, DGRh, DEGAM, DWG, DVMB, DOG, DRG, DGMM, DGPMR/DGRW, Physio Deutschland, DDG, DGOOC, DGIM, DGOOC/DGORh, DGNC

Erschienen in: Zeitschrift für Rheumatologie | Sonderheft 1/2019

Einloggen, um Zugang zu erhalten

Auszug

Version: 2018 …
Anhänge
Nur mit Berechtigung zugänglich
Fußnoten
1
Die Mehrzahl der in dieser Leitlinie genannten Studien bezieht sich auf Patienten mit AS. Gerade in jüngster Zeit sind aber auch viele Studien, die Patienten mit nr-axSpA umfassen, publiziert worden. Im klinischen Alltag hat diese artifizielle Einteilung nur eine untergeordnete Bedeutung und spielt im Wesentlichen eine Rolle bei der Indikation für eine Biologikatherapie. Die überwiegende Anzahl der medikamentösen Therapien ist in Deutschland für Patienten mit AS. Seit 2012 sind bis auf Infliximab alle TNFi für die Behandlung symptomatischer Patienten mit nr-axSpA und objektivem Entzündungsnachweis* zugelassen (Abschn. 8.4.2) (*Die modifizierten New-York-Kriterien dienen zur Charakterisierung des röntgenologischen Stadiums und werden im Abschn. 4.2 und 6.1.1.1 näher erläutert).
 
2
Die Zulassungsstudie zur nr-axSpA wird gerade durchgeführt.
 
3
Nach Fertigstellung der SLR wurde eine kontrollierte Studie bei Patienten mit nr-axSpA publiziert, in der gezeigt wurde, dass bei Patienten in klinischer Remission unter einer Therapie mit Adalimumab das Absetzen der bDMARD-Therapie zwar zu einer höheren Rate an Schüben führte, aber dass trotzdem 47 % der Patienten in dem Beobachtungszeitraum keinen Schub erlitten [516].
 
Literatur
1.
2.
Rudwaleit M et al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777–783PubMedCrossRef
3.
Rudwaleit M et al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 68(6):770–776PubMedCrossRef
4.
Dean LE et al (2014) Global prevalence of ankylosing spondylitis. Rheumatol (oxford) 53(4):650–657CrossRef
5.
Braun J et al (1998) Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 41(1):58–67PubMedCrossRef
6.
Almodovar R et al (2011) Phenotypic differences between familial versus sporadic ankylosing spondylitis: a cross-sectional Spanish registry of spondyloarthropathies (REGISPONSER). Clin Exp Rheumatol 29(5):822–827PubMed
7.
Chen HA et al (2012) Clinical, functional, and radiographic differences among juvenile-onset, adult-onset, and late-onset ankylosing spondylitis. J Rheumatol 39(5):1013–1018PubMedCrossRef
8.
Jamalyaria F et al (2017) Ethnicity and disease severity in ankylosing spondylitis a cross-sectional analysis of three ethnic groups. Clin Rheumatol 36(10):2359–2364PubMedPubMedCentralCrossRef
9.
Skare TL et al (2012) Effect of age at disease onset in the clinical profile of spondyloarthritis: a study of 1424 Brazilian patients. Clin Exp Rheumatol 30(3):351–357PubMed
10.
Landewe R et al (2009) Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis 68(6):863–867PubMedCrossRef
11.
Ward MM et al (2008) Impact of ankylosing spondylitis on work and family life: comparisons with the US population. Arthritis Rheum 59(4):497–503PubMedCrossRef
12.
Dagfinrud H et al (2005) Impact of functional impairment in ankylosing spondylitis: impairment, activity limitation, and participation restrictions. J Rheumatol 32(3):516–523PubMed
13.
Mau W et al (2005) Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol 32(4):721–728PubMed
14.
Boonen A et al (2010) Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Ann Rheum Dis 69(6):1123–1128PubMedCrossRef
15.
Calin A et al (1980) The prevalence and nature of back pain in an industrial complex: a questionnaire and radiographic and HLA analysis. Spine (phila Pa 1976) 5(2):201–205CrossRef
16.
Feldtkeller E et al (2003) Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 23(2):61–66PubMedCrossRef
17.
van der Linden SM et al (1984) The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 27(3):241–249PubMedCrossRef
18.
Sorensen J, Hetland ML, D. all departments of rheumatology (2015) in, Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 74(3):e12PubMedCrossRef
19.
Burgos-Varga R et al (2016) The prevalence and clinical characteristics of nonradiographic axial spondyloarthritis among patients with inflammatory back pain in rheumatology practices: a multinational, multicenter study. Arthritis Res Ther 18(1):132PubMedPubMedCentralCrossRef
20.
Zink A et al (2000) Disability and handicap in rheumatoid arthritis and ankylosing spondylitis—results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 27(3):613–622PubMed
21.
van der Heijde D et al (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76(6):978–991PubMedCrossRef
22.
Rojas-Vargas M et al (2009) First signs and symptoms of spondyloarthritis—data from an inception cohort with a disease course of two years or less (REGISPONSER-Early). Rheumatol (oxford) 48(4):404–409CrossRef
23.
Hamilton L et al (2014) The prevalence of inflammatory back pain in a UK primary care population. Rheumatol (oxford) 53(1):161–164CrossRef
24.
Calin A et al (1977) Clinical history as a screening test for ankylosing spondylitis. JAMA 237(24):2613–2614PubMedCrossRef
25.
Rudwaleit M et al (2006) Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 54(2):569–578PubMedCrossRef
26.
Sieper J et al (2009) New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis 68(6):784–788PubMedCrossRef
27.
Solmaz D et al (2014) Performance of different criteria sets for inflammatory back pain in patients with axial spondyloarthritis with and without radiographic sacroiliitis. Clin Rheumatol 33(10):1475–1479PubMedCrossRef
28.
Gazeau P et al (2018) Classification criteria versus physician’s opinion for considering a patient with inflammatory back pain as suffering from spondyloarthritis. Joint Bone Spine 85(1):85–91PubMedCrossRef
29.
Machado P et al (2010) Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis 69(8):1465–1470PubMedCrossRef
30.
Weber U et al (2012) Anterior chest wall inflammation by whole-body magnetic resonance imaging in patients with spondyloarthritis: lack of association between clinical and imaging findings in a cross-sectional study. Arthritis Res Ther 14(1):R3PubMedPubMedCentralCrossRef
31.
Payet J et al (2012) Prevalence and clinical characteristics of dactylitis in spondylarthritis: a descriptive analysis of 275 patients. Clin Exp Rheumatol 30(2):191–196PubMed
32.
Navarro-Compan V et al (2015) Sponyloarthritis features forecasting the presence of HLA-B27 or sacroiliitis on magnetic resonance imaging in patients with suspected axial spondyloarthritis: results from a cross-sectional study in the ESPeranza Cohort. Arthritis Res Ther 17:265PubMedPubMedCentralCrossRef
33.
Bethi S et al (2013) Functional limitations due to axial and peripheral joint impairments in patients with ankylosing spondylitis: are focused measures more informative? Arthritis Care Res (hoboken) 65(4):607–614CrossRef
34.
Aydin SZ et al (2016) A relationship between spinal new bone formation in ankylosing spondylitis and the sonographically determined Achilles tendon enthesophytes. Rheumatol Int 36(3):397–404PubMedCrossRef
35.
Ruta S et al (2011) Prevalence of subclinical enthesopathy in patients with spondyloarthropathy: an ultrasound study. J Clin Rheumatol 17(1):18–22PubMedCrossRef
36.
Maksymowych WP et al (2009) Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis 68(6):948–953PubMedCrossRef
37.
Heuft-Dorenbosch L et al (2003) Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 62(2):127–132PubMedCrossRef
38.
Tournadre A et al (2013) Differences between women and men with recent onset axial spondyloarthritis: results from the DESIR cohort. Arthritis Care Res (hoboken) 65(9):1482–1489CrossRef
39.
Webers C et al (2016) Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. Rheumatol (oxford) 55(3):419–428
40.
van der Horst-Bruinsma IE et al (2013) Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies. Ann Rheum Dis 72(7):1221–1224PubMedCrossRef
41.
Landi M et al (2016) Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort. Medicine (Baltimore) 95(51):e5652CrossRef
42.
Sidiropoulos PI et al (2008) Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatol (oxford) 47(3):355–361CrossRef
43.
44.
Karberg K et al (2005) Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 32(7):1290–1298PubMed
45.
Wang D et al (2017) Bone edema on magnetic resonance imaging is highly associated with low bone mineral density in patients with ankylosing spondylitis. PLoS ONE 12(12):e189569PubMedPubMedCentralCrossRef
46.
Briot K et al (2016) Bone loss in patients with early inflammatory back pain suggestive of spondyloarthritis: results from the prospective DESIR cohort. Rheumatol (oxford) 55(2):335–342CrossRef
47.
Gratacos J et al (1999) Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. Arthritis Rheum 42(11):2319–2324PubMedCrossRef
48.
Prieto-Alhambra D et al (2015) Ankylosing spondylitis confers substantially increased risk of clinical spine fractures: a nationwide case-control study. Osteoporos Int 26(1):85–91PubMedCrossRef
49.
Jun JB et al (2006) Femoral bone mineral density is associated with vertebral fractures in patients with ankylosing spondylitis: a cross-sectional study. J Rheumatol 33(8):1637–1641PubMed
50.
Vosse D et al (2009) Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis 68(12):1839–1842PubMedCrossRef
51.
Deminger A et al (2017) Which measuring site in ankylosing spondylitis is best to detect bone loss and what predicts the decline: results from a 5-year prospective study. Arthritis Res Ther 19(1):273PubMedPubMedCentralCrossRef
52.
Montala N et al (2011) Prevalence of vertebral fractures by semiautomated morphometry in patients with ankylosing spondylitis. J Rheumatol 38(5):893–897PubMedCrossRef
53.
Westerveld LA, Verlaan JJ, Oner FC (2009) Spinal fractures in patients with ankylosing spinal disorders: a systematic review of the literature on treatment, neurological status and complications. Eur Spine J 18(2):145–156PubMedCrossRef
54.
Dursun N et al (2015) Risk of falls in patients with ankylosing spondylitis. J Clin Rheumatol 21(2):76–80PubMedCrossRef
55.
Protopopov M et al (2017) Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Res Ther 19(1):240PubMedPubMedCentralCrossRef
56.
Haywood KL et al (2004) Spinal mobility in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatol (oxford) 43(6):750–757CrossRef
57.
Wanders A et al (2005) Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis 64(7):988–994PubMedPubMedCentralCrossRef
58.
Heuft-Dorenbosch L et al (2004) Measurement of spinal mobility in ankylosing spondylitis: comparison of occiput-to-wall and tragus-to-wall distance. J Rheumatol 31(9):1779–1784PubMed
59.
Deyo RA, Diehr P, Patrick DL (1991) Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials 12(4 Suppl):142S–158SPubMedCrossRef
60.
Pile KD et al (1991) Clinical assessment of ankylosing spondylitis: a study of observer variation in spinal measurements. Br J Rheumatol 30(1):29–34PubMedCrossRef
61.
Gladman DD et al (2007) International spondyloarthritis interobserver reliability exercise—the INSPIRE study: I. Assessment of spinal measures. J Rheumatol 34(8):1733–1739PubMed
62.
Kennedy LG et al (1995) Ankylosing spondylitis: the correlation between a new metrology score and radiology. Br J Rheumatol 34(8):767–770PubMedCrossRef
63.
Chandran V et al (2007) Relationship between spinal mobility and radiographic damage in ankylosing spondylitis and psoriatic spondylitis: a comparative analysis. J Rheumatol 34(12):2463–2465PubMed
64.
Shin JK et al (2014) Correlation between clinical outcome and spinopelvic parameters in ankylosing spondylitis. Eur Spine J 23(1):242–247PubMedCrossRef
65.
Jenkinson TR et al (1994) Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 21(9):1694–1698PubMed
66.
Calin A et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281–2285PubMed
67.
Garrett S et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291PubMed
68.
Ruof J, Sangha O, Stucki G (1999) Evaluation of a German version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Dougados Functional Index (D-FI). Z Rheumatol 58(4):218–225PubMedCrossRef
69.
Boonen A et al (2009) Spinal radiographic changes in ankylosing spondylitis: association with clinical characteristics and functional outcome. J Rheumatol 36(6):1249–1255PubMedCrossRef
70.
Ward MM et al (2005) Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. Arthritis Rheum 53(5):710–717PubMedPubMedCentralCrossRef
71.
Daltroy LH et al (1990) A modification of the Health Assessment Questionnaire for the spondyloarthropathies. J Rheumatol 17(7):946–950PubMed
72.
Vander Cruyssen B et al (2007) The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis 66(8):1072–1077PubMedCrossRef
73.
Brophy S, Calin A (2001) Ankylosing spondylitis: interaction between genes, joints, age at onset, and disease expression. J Rheumatol 28(10):2283–2288PubMed
74.
Rudwaleit M et al (2009) The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 60(3):717–727PubMedCrossRef
75.
Kiltz U et al (2012) Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res (hoboken) 64(9):1415–1422CrossRef
76.
Stolwijk C et al (2015) Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis 74(1):65–73PubMedCrossRef
77.
Collantes E et al (2007) Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report. Rheumatol (oxford) 46(8):1309–1315CrossRef
78.
Bremander A et al (2011) Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (hoboken) 63(4):550–556CrossRef
79.
Chorus AM et al (2003) Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis 62(12):1178–1184PubMedPubMedCentralCrossRef
80.
Sampaio-Barros PD et al (2013) An analysis of 372 patients with anterior uveitis in a large Ibero-American cohort of spondyloarthritis: the RESPONDIA Group. Clin Exp Rheumatol 31(4):484–489PubMed
81.
Canoui-Poitrine F et al (2012) Prevalence and factors associated with uveitis in spondylarthritis patients in France: results from an observational survey. Arthritis Care Res (hoboken) 64(6):919–924CrossRef
82.
Zeboulon N, Dougados M, Gossec L (2008) Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 67(7):955–959PubMedCrossRef
83.
Essers I et al (2015) Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. Rheumatol (oxford) 54(4):633–640CrossRef
84.
Robinson PC et al (2015) Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis. Arthritis Rheumatol 67(1):140–151PubMedPubMedCentralCrossRef
85.
Rosenbaum JT (1992) Acute anterior uveitis and spondyloarthropathies. Rheum Dis Clin North Am 18(1):143–151PubMed
86.
Accorinti M et al (2010) Clinical features and prognosis of HLA B27-associated acute anterior uveitis in an Italian patient population. Ocul Immunol Inflamm 18(2):91–96PubMedCrossRef
87.
Munoz-Fernandez S et al (2003) Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol 30(6):1277–1279PubMed
88.
Benitez-Del-Castillo JM et al (2000) Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond) 14(Pt 3A):340–343CrossRef
89.
Nguyen QD et al (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 388(10050):1183–1192PubMedCrossRef
90.
Braun J et al (2005) Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52(8):2447–2451PubMedCrossRef
91.
Sieper J et al (2010) Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 69(1):226–229PubMedCrossRef
92.
Gao X et al (2012) Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. J Med Econ 15(6):1054–1063PubMedCrossRef
93.
Lie E et al (2017) Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Ann Rheum Dis 76(9):1515–1521PubMedCrossRef
94.
Wendling D et al (2014) Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res Opin 30(12):2515–2521PubMedCrossRef
95.
Rudwaleit M et al (2009) Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 68(5):696–701PubMedCrossRef
96.
Dick AD et al (2013) Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 120(4):777–787PubMedCrossRef
97.
Letko E et al (2015) Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology 122(5):939–948PubMedCrossRef
98.
Mielants H et al (1996) Course of gut inflammation in spondylarthropathies and therapeutic consequences. Baillieres Clin Rheumatol 10(1):147–164PubMedCrossRef
99.
Mielants H et al (1995) The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 22(12):2279–2284PubMed
100.
D’Inca R et al (2009) Articular manifestations in inflammatory bowel disease patients: a prospective study. Dig Liver Dis 41(8):565–569PubMedCrossRef
101.
Peeters H et al (2008) Clinical and genetic factors associated with sacroiliitis in Crohn’s disease. J Gastroenterol Hepatol 23(1):132–137PubMed
102.
Vavricka SR et al (2011) Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 106(1):110–119PubMedCrossRef
103.
El Miedany Y et al (2006) The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 101(2):311–317PubMedCrossRef
104.
Hoffmann JC et al (2008) Clinical practice guideline on diagnosis and treatment of Crohn’s disease. Z Gastroenterol 46(9):1094–1146PubMedCrossRef
105.
Braun J et al (2007) Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 57(4):639–647PubMedCrossRef
106.
Toussirot E et al (2012) Development of inflammatory bowel disease during anti-TNF-alpha therapy for inflammatory rheumatic disease. A nationwide series. Joint Bone Spine 79(5):457–463PubMedCrossRef
107.
Hueber W et al (2012) Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61(12):1693–1700PubMedCrossRef
108.
Bergfeldt L et al (1982) Ankylosing spondylitis: an important cause of severe disturbances of the cardiac conduction system. Prevalence among 223 pacemaker-treated men. Am J Med 73(2):187–191PubMedCrossRef
109.
110.
Bengtsson K et al (2018) Risk of cardiac rhythm disturbances and aortic regurgitation in different spondyloarthritis subtypes in comparison with general population: a register-based study from Sweden. Ann Rheum Dis 77(4):541–548PubMedCrossRef
111.
Sampaio-Barros PD et al (2007) Pulmonary involvement in ankylosing spondylitis. Clin Rheumatol 26(2):225–230PubMedCrossRef
112.
El Maghraoui A et al (2004) Lung findings on thoracic high-resolution computed tomography in patients with ankylosing spondylitis. Correlations with disease duration, clinical findings and pulmonary function testing. Clin Rheumatol 23(2):123–128PubMedCrossRef
113.
Souza AS Jr. et al (2004) Pulmonary abnormalities in ankylosing spondylitis: inspiratory and expiratory high-resolution CT findings in 17 patients. J Thorac Imaging 19(4):259–263PubMedCrossRef
114.
Gratacos J et al (1997) Secondary amyloidosis in ankylosing spondylitis. A systematic survey of 137 patients using abdominal fat aspiration. J Rheumatol 24(5):912–915PubMed
115.
Lee SH et al (2013) Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker. Rheumatol Int 33(7):1689–1692PubMedCrossRef
116.
Jakobsen AK et al (2014) Is nephrolithiasis an unrecognized extra-articular manifestation in ankylosing spondylitis? A prospective population-based Swedish national cohort study with matched general population comparator subjects. PLoS ONE 9(11):e113602PubMedPubMedCentralCrossRef
117.
Molto A et al (2016) Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis 75(6):1016–1023PubMedCrossRef
118.
Hmamouchi I et al (2016) Vitamin D, disease activity and comorbidities in early spondyloarthritis. Clin Exp Rheumatol 34(3):396–403PubMed
119.
Meesters JJ et al (2014) The risk for depression in patients with ankylosing spondylitis: a population-based cohort study. Arthritis Res Ther 16(5):418PubMedPubMedCentralCrossRef
120.
Li Y et al (2012) Sleep disturbances are associated with increased pain, disease activity, depression, and anxiety in ankylosing spondylitis: a case-control study. Arthritis Res Ther 14(5):R215PubMedPubMedCentralCrossRef
121.
Dhakad U et al (2015) Sexual dysfunctions and lower urinary tract symptoms in ankylosing spondylitis. Int J Rheum Dis 18(8):866–872PubMedCrossRef
122.
Dau JD et al (2018) Opioid analgesic use in patients with Ankylosing Spondylitis: an analysis of the prospective study of outcomes in an Ankylosing Spondylitis cohort. J Rheumatol 45(2):188–194PubMedCrossRef
123.
Maas F et al (2016) Obesity is common in axial Spondyloarthritis and is associated with poor clinical outcome. J Rheumatol 43(2):383–387PubMedCrossRef
124.
Baraliakos X et al (2018) Patients with fibromyalgia rarely fulfil classification criteria for axial spondyloarthritis. Rheumatol (oxford) 57(9):1541–1547CrossRef
125.
Molto A et al (2018) Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers’ effectiveness in axial spondyloarthritis: results of a prospective, multicentre study. Ann Rheum Dis 77(4):533–540PubMedCrossRef
126.
Macfarlane GJ et al (2017) Co-occurrence and characteristics of patients with axial Spondyloarthritis who meet criteria for Fibromyalgia: results from a UK national register. Arthritis Rheumatol 69(11):2144–2150PubMedCrossRef
127.
Peters MJ et al (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34(3):585–592PubMedCrossRef
128.
Haroon NN et al (2015) Patients with Ankylosing Spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med 163(6):409–416PubMedCrossRef
129.
Heeneman S, Daemen MJ (2007) Cardiovascular risks in spondyloarthritides. Curr Opin Rheumatol 19(4):358–362PubMedCrossRef
130.
Arida A et al (2015) Subclinical atherosclerosis is not accelerated in patients with Ankylosing Spondylitis with low disease activity: new data and metaanalysis of published studies. J Rheumatol 42(11):2098–2105PubMedCrossRef
131.
Chen Y et al (2015) Left ventricular myocardial dysfunction and premature atherosclerosis in patients with axial spondyloarthritis. Rheumatol (oxford) 54(2):292–301CrossRef
132.
Choe JY et al (2008) No differences of carotid intima-media thickness between young patients with ankylosing spondylitis and healthy controls. Joint Bone Spine 75(5):548–553PubMedCrossRef
133.
Gonzalez-Juanatey C et al (2009) The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 88(6):358–365CrossRef
134.
Peters MJ et al (2010) Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 37(1):161–166PubMedCrossRef
135.
Bengtsson K et al (2017) Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Arthritis Res Ther 19(1):102PubMedPubMedCentralCrossRef
136.
Peters MJ et al (2010) Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis 69(3):579–581PubMedCrossRef
137.
Mathieu S et al (2011) Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (hoboken) 63(4):557–563CrossRef
138.
van Halm VP et al (2006) Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. Ann Rheum Dis 65(11):1473–1477PubMedPubMedCentralCrossRef
139.
Berg IJ et al (2015) Disease activity in ankylosing spondylitis and associations to markers of vascular pathology and traditional cardiovascular disease risk factors: a cross-sectional study. J Rheumatol 42(4):645–653PubMedCrossRef
140.
Spanakis E et al (2006) Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 33(12):2440–2446PubMed
141.
van Eijk IC et al (2009) Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum 60(5):1324–1330PubMedCrossRef
142.
van Eijk IC et al (2009) Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis 68(3):362–366PubMedCrossRef
143.
Peters MJ et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69(2):325–331PubMedCrossRef
144.
Bianchi WA et al (2014) Assessment of fatigue in a large series of 1492 Brazilian patients with Spondyloarthritis. Mod Rheumatol 24(6):980–984PubMedCrossRef
145.
Alkan BM et al (2013) Fatigue and correlation with disease-specific variables, spinal mobility measures, and health-related quality of life in ankylosing spondylitis. Mod Rheumatol 23(6):1101–1107PubMedCrossRef
146.
van Tubergen A et al (2002) Assessment of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum 47(1):8–16PubMedCrossRef
147.
Jones SD et al (1996) Fatigue in ankylosing spondylitis: its prevalence and relationship to disease activity, sleep, and other factors. J Rheumatol 23(3):487–490PubMed
148.
Bedaiwi M et al (2015) Fatigue in Ankylosing Spondylitis and Nonradiographic axial Spondyloarthritis: analysis from a longitudinal observation cohort. J Rheumatol 42(12):2354–2360PubMedCrossRef
149.
Dagfinrud H et al (2005) Fatigue in patients with ankylosing spondylitis: a comparison with the general population and associations with clinical and self-reported measures. Arthritis Rheum 53(1):5–11PubMedCrossRef
150.
Chauffier K et al (2013) Fatigue in spondyloarthritis: a marker of disease activity. A cross-sectional study of 266 patients. Clin Exp Rheumatol 31(6):864–870PubMed
151.
Gossec L et al (2016) Fatigue in early axial spondyloarthritis. Results from the French DESIR cohort. Joint Bone Spine 83(4):427–431PubMedCrossRef
152.
van der Heijde DM et al (2009) Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther 11(4):R124PubMedPubMedCentralCrossRef
153.
Revicki DA et al (2008) Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). J Rheumatol 35(7):1346–1353PubMed
154.
Espahbodi S et al (2017) Fatigue contributes to work productivity impairment in patients with axial spondyloarthritis: a cross-sectional UK study. Clin Exp Rheumatol 35(4):571–578PubMed
155.
Zochling J, Braun J (2009) Mortality in rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 27(4 Suppl 55):S127–30PubMed
156.
Brown WM, Doll R (1965) Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis. Br Med J 2(5474):1327–1332PubMedPubMedCentralCrossRef
157.
Exarchou S et al (2016) Mortality in ankylosing spondylitis: results from a nationwide population-based study. Ann Rheum Dis 75(8):1466–1472PubMedCrossRef
158.
Oza A et al (2017) Survival benefit of statin use in ankylosing spondylitis: a general population-based cohort study. Ann Rheum Dis 76(10):1737–1742PubMedCrossRef
159.
Bakland G, Gran JT, Nossent JC (2011) Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 70(11):1921–1925PubMedCrossRef
160.
Zink A, Minden K (2010) Entzündlich rheumatische Erkrankungen. Gesundheitsberichterstattung des Bundes, Bd. 49. R.-K.I., Berlin
161.
Wysham KD et al (2017) Cervical spinal fracture and other diagnoses associated with mortality in hospitalized Ankylosing Spondylitis patients. Arthritis Care Res (hoboken) 69(2):271–277CrossRef
162.
Wick RR et al (2008) Increased risk of myeloid leukaemia in patients with ankylosing spondylitis following treatment with radium-224. Rheumatol (oxford) 47(6):855–859CrossRef
163.
Rudwaleit M et al (2011) The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70(1):25–31PubMedCrossRef
164.
Amor B, Dougados M, Mijiyawa M (1990) Criteria of the classification of spondylarthropathies. Rev Rhum Mal Osteoartic 57(2):85–89PubMed
165.
Dougados M et al (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34(10):1218–1227PubMedCrossRef
166.
167.
Aydin SZ et al (2012) Validation of the ASAS criteria and definition of a positive MRI of the sacroiliac joint in an inception cohort of axial spondyloarthritis followed up for 8 years. Ann Rheum Dis 71(1):56–60PubMedCrossRef
168.
Sepriano A et al (2016) Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. Ann Rheum Dis 75(6):1034–1042PubMedCrossRef
169.
Molto A et al (2013) Performances of the Assessment of SpondyloArthritis International Society axial spondyloarthritis criteria for diagnostic and classification purposes in patients visiting a rheumatologist because of chronic back pain: results from a multicenter, cross-sectional study. Arthritis Care Res (hoboken) 65(9):1472–1481CrossRef
170.
Molto A et al (2014) Evaluation of the validity of the different arms of the ASAS set of criteria for axial spondyloarthritis and description of the different imaging abnormalities suggestive of spondyloarthritis: data from the DESIR cohort. Ann Rheum Dis 74(4):746–751PubMedCrossRef
171.
172.
Ez-Zaitouni Z et al (2017) Presence of multiple spondyloarthritis (SpA) features is important but not sufficient for a diagnosis of axial spondyloarthritis: data from the SPondyloArthritis Caught Early (SPACE) cohort. Ann Rheum Dis 76(6):1086–1092PubMedCrossRef
173.
Bakker PA et al (2016) Are additional tests needed to rule out axial Spondyloarthritis in patients ages 16–45 years with short-duration chronic back pain and maximally one Spondyloarthritis feature? Arthritis Care Res (hoboken) 68(11):1726–1730CrossRef
174.
Joven BE et al (2017) Diagnostic value and validity of early Spondyloarthritis features: results from a national Spanish cohort. Arthritis Care Res (hoboken) 69(6):938–942CrossRef
175.
van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368PubMedCrossRef
176.
Wallman JK et al (2015) Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients—baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice. Arthritis Res Ther 17(1):378PubMedPubMedCentralCrossRef
177.
Malaviya AN et al (2015) Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi. Int J Rheum Dis 18(7):736–741PubMedCrossRef
178.
Glintborg B et al (2017) Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry. J Rheumatol 44(1):59–69PubMedCrossRef
179.
Sieper J, Rudwaleit M (2005) Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis 64(5):659–663PubMedCrossRef
180.
Heuft-Dorenbosch L et al (2007) Performance of various criteria sets in patients with inflammatory back pain of short duration; the Maastricht early spondyloarthritis clinic. Ann Rheum Dis 66(1):92–98PubMedCrossRef
181.
Dean LE, Macfarlane GJ, Jones GT (2016) Differences in the prevalence of ankylosing spondylitis in primary and secondary care: only one-third of patients are managed in rheumatology. Rheumatol (oxford) 55(10):1820–1825CrossRef
182.
Deodhar A et al (2016) Ankylosing spondylitis diagnosis in US patients with back pain: identifying providers involved and factors associated with rheumatology referral delay. Clin Rheumatol 35(7):1769–1776PubMedPubMedCentralCrossRef
183.
Underwood MR, Dawes P (1995) Inflammatory back pain in primary care. Br J Rheumatol 34(11):1074–1077PubMedCrossRef
184.
Strand V et al (2013) Prevalence of axial spondyloarthritis in United States rheumatology practices: Assessment of SpondyloArthritis International Society criteria versus rheumatology expert clinical diagnosis. Arthritis Care Res (hoboken) 65(8):1299–1306CrossRef
185.
Liao ZT et al (2009) An epidemiological survey of low back pain and axial spondyloarthritis in a Chinese Han population. Scand J Rheumatol 38(6):455–459PubMedCrossRef
186.
Weisman MH, Witter JP, Reveille JD (2013) The prevalence of inflammatory back pain: population-based estimates from the US National Health and Nutrition Examination Survey, 2009–10. Ann Rheum Dis 72(3):369–373PubMedCrossRef
187.
Jois RN, Macgregor AJ, Gaffney K (2008) Recognition of inflammatory back pain and ankylosing spondylitis in primary care. Rheumatol (oxford) 47(9):1364–1366CrossRef
188.
Brandt HC et al (2007) Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. Ann Rheum Dis 66(11):1479–1484PubMedPubMedCentralCrossRef
189.
Hermann J et al (2009) Early spondyloarthritis: usefulness of clinical screening. Rheumatol (oxford) 48(7):812–816CrossRef
190.
Braun A et al (2011) Identifying patients with axial spondyloarthritis in primary care: how useful are items indicative of inflammatory back pain? Ann Rheum Dis 70(10):1782–1787PubMedCrossRef
191.
Poddubnyy D et al (2011) Evaluation of 2 screening strategies for early identification of patients with axial spondyloarthritis in primary care. J Rheumatol 38(11):2452–2460PubMedCrossRef
192.
Sampaio-Barros PD et al (2010) Undifferentiated spondyloarthritis: a longterm followup. J Rheumatol 37(6):1195–1199PubMedCrossRef
193.
Freeston J et al (2007) Ankylosing spondylitis, HLA-B27 positivity and the need for biologic therapies. Joint Bone Spine 74(2):140–143PubMedCrossRef
194.
Chung HY et al (2011) HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging: results from the DESIR cohort of patients with recent onset axial spondyloarthritis. Ann Rheum Dis 70(11):1930–1936PubMedCrossRef
195.
van Onna M et al (2011) HLA-B27 and gender independently determine the likelihood of a positive MRI of the sacroiliac joints in patients with early inflammatory back pain: a 2-year MRI follow-up study. Ann Rheum Dis 70(11):1981–1985PubMedCrossRef
196.
Linssen A (1990) B27+ disease versus B27− disease. Scand J Rheumatol Suppl 87:111–118 (discussion 118–9)PubMedCrossRef
197.
Khan MA, Kushner I, Braun WE (1977) Comparison of clinical features in HLA-B27 positive and negative patients with ankylosing spondylitis. Arthritis Rheum 20(4):909–912PubMedCrossRef
198.
Kim TJ et al (2009) HLA-B27 homozygosity has no influence on clinical manifestations and functional disability in ankylosing spondylitis. Clin Exp Rheumatol 27(4):574–579PubMed
199.
Lin H, Gong YZ (2017) Association of HLA-B27 with ankylosing spondylitis and clinical features of the HLA-B27-associated ankylosing spondylitis: a meta-analysis. Rheumatol Int 37(8):1267–1280PubMedCrossRef
200.
Spoorenberg A et al (1999) Relative value of erythrocyte sedimentation rate and C‑reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 26(4):980–984PubMed
201.
Braun A et al (2013) Optimizing the identification of patients with axial spondyloarthritis in primary care—the case for a two-step strategy combining the most relevant clinical items with HLA B27. Rheumatol (oxford) 52(8):1418–1424CrossRef
202.
van Hoeven L et al (2014) Identifying axial spondyloarthritis in Dutch primary care patients, ages 20–45 years, with chronic low back pain. Arthritis Care Res (hoboken) 66(3):446–453CrossRef
203.
Sieper J et al (2013) Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study. Ann Rheum Dis 72(10):1621–1627PubMedCrossRef
204.
Abawi O et al (2017) Evaluation of multiple referral strategies for axial spondyloarthritis in the SPondyloArthritis Caught Early (SPACE) cohort. RMD Open 3(1):e389PubMedPubMedCentralCrossRef
205.
Baraliakos X et al (2008) The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther 10(5):R104PubMedPubMedCentralCrossRef
206.
Maksymowych WP et al (2009) Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 60(1):93–102PubMedCrossRef
207.
Chiowchanwisawakit P et al (2011) Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum 63(8):2215–2225PubMedCrossRef
208.
Pedersen SJ et al (2011) Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor alpha inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover. Arthritis Rheum 63(12):3789–3800PubMedCrossRef
209.
Pedersen SJ et al (2011) Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation. J Rheumatol 38(7):1349–1354PubMedCrossRef
210.
Baraliakos X et al (2007) Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 66(7):910–915PubMedPubMedCentralCrossRef
211.
Diarra D et al (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13(2):156–163PubMedCrossRef
212.
Daoussis D et al (2010) Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 62(1):150–158PubMedCrossRef
213.
Appel H et al (2009) Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 60(11):3257–3262PubMedCrossRef
214.
Mau W et al (1988) Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol 15(7):1109–1114PubMed
215.
Poddubnyy D et al (2011) Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis 70(8):1369–1374PubMedCrossRef
216.
Dougados M et al (2017) Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5‑year data of the DESIR cohort. Ann Rheum Dis 76(11):1823–1828PubMedCrossRef
217.
Wang R, Gabriel SE, Ward MM (2016) Progression of Nonradiographic axial Spondyloarthritis to Ankylosing Spondylitis: a population-based cohort study. Arthritis Rheumatol 68(6):1415–1421PubMedPubMedCentralCrossRef
218.
Baraliakos X et al (2009) Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: addition of the thoracic spine improves sensitivity to change. Arthritis Rheum 61(6):764–771PubMedCrossRef
219.
Lee JS et al (2015) Relationship between cervical sagittal alignment and quality of life in ankylosing spondylitis. Eur Spine J 24(6):1199–1203PubMedCrossRef
220.
Baraliakos X et al (2011) The natural course of radiographic progression in ankylosing spondylitis: differences between genders and appearance of characteristic radiographic features. Curr Rheumatol Rep 13(5):383–387PubMedCrossRef
221.
Poddubnyy D et al (2016) High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort. Ann Rheum Dis 75(12):2114–2118PubMedCrossRef
222.
van Tubergen A et al (2012) Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. Ann Rheum Dis 71(4):518–523PubMedCrossRef
223.
Ramiro S et al (2014) Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis 73(8):1455–1461PubMedCrossRef
224.
Poddubnyy D et al (2012) Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 64(5):1388–1398PubMedCrossRef
225.
van der Heijde D et al (2008) Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 58(10):3063–3070PubMedCrossRef
226.
MacKay K et al (1998) The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum 41(12):2263–2270PubMedCrossRef
227.
Averns HL et al (1996) Radiological outcome in ankylosing spondylitis: use of the Stoke Ankylosing Spondylitis Spine Score (SASSS). Br J Rheumatol 35(4):373–376PubMedCrossRef
228.
Creemers MC et al (2005) Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 64(1):127–129PubMedCrossRef
229.
Salaffi F et al (2007) Radiological scoring methods for ankylosing spondylitis: a comparison between the Bath Ankylosing Spondylitis Radiology Index and the modified Stoke Ankylosing Spondylitis Spine Score. Clin Exp Rheumatol 25(1):67–74PubMed
230.
de Bruin F et al (2016) Prevalence of degenerative changes of the spine on magnetic resonance images and radiographs in patients aged 16–45 years with chronic back pain of short duration in the Spondyloarthritis Caught Early (SPACE) cohort. Rheumatol (oxford) 55(1):56–65CrossRef
231.
Vosse D et al (2007) Comparing morphometric X‑ray absorptiometry and radiography in defining vertebral wedge fractures in patients with ankylosing spondylitis. Rheumatol (oxford) 46(11):1667–1671CrossRef
232.
Diekhoff T et al (2017) Comparison of MRI with radiography for detecting structural lesions of the sacroiliac joint using CT as standard of reference: results from the SIMACT study. Ann Rheum Dis 76(9):1502–1508PubMedCrossRef
233.
Baraliakos X et al (2005) Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences. Ann Rheum Dis 64(8):1141–1144PubMedPubMedCentralCrossRef
234.
Rudwaleit M et al (2009) Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 68(10):1520–1527PubMedCrossRef
235.
Weber U et al (2009) Sensitivity and specificity of spinal inflammatory lesions assessed by whole-body magnetic resonance imaging in patients with ankylosing spondylitis or recent-onset inflammatory back pain. Arthritis Rheum 61(7):900–908PubMedCrossRef
236.
Althoff CE et al (2013) Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRI. Ann Rheum Dis 72(6):967–973PubMedCrossRef
237.
Weber U et al (2009) Validation of whole-body against conventional magnetic resonance imaging for scoring acute inflammatory lesions in the sacroiliac joints of patients with spondylarthritis. Arthritis Rheum 61(7):893–899PubMedCrossRef
238.
Weber U et al (2010) Assessment of active spinal inflammatory changes in patients with axial spondyloarthritis: validation of whole body MRI against conventional MRI. Ann Rheum Dis 69(4):648–653PubMedCrossRef
239.
Bollow M et al (2000) Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis—cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 59(2):135–140PubMedPubMedCentralCrossRef
240.
Gong Y et al (2012) Ten years’ experience with needle biopsy in the early diagnosis of sacroiliitis. Arthritis Rheum 64(5):1399–1406PubMedCrossRef
241.
Muche B et al (2003) Anatomic structures involved in early- and late-stage sacroiliitis in spondylarthritis: a detailed analysis by contrast-enhanced magnetic resonance imaging. Arthritis Rheum 48(5):1374–1384PubMedCrossRef
242.
Madsen KB, Jurik AG (2010) Magnetic resonance imaging grading system for active and chronic spondylarthritis changes in the sacroiliac joint. Arthritis Care Res (hoboken) 62(1):11–18CrossRef
243.
Madsen KB, Egund N, Jurik AG (2010) Grading of inflammatory disease activity in the sacroiliac joints with magnetic resonance imaging: comparison between short-tau inversion recovery and gadolinium contrast-enhanced sequences. J Rheumatol 37(2):393–400PubMedCrossRef
244.
Marzo-Ortega H et al (2009) Baseline and 1‑year magnetic resonance imaging of the sacroiliac joint and lumbar spine in very early inflammatory back pain. Relationship between symptoms, HLA-B27 and disease extent and persistence. Ann Rheum Dis 68(11):1721–1727PubMedCrossRef
245.
Song IH et al (2011) Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. Ann Rheum Dis 70(7):1257–1263PubMedCrossRef
246.
Hu Z et al (2016) Backfill is a specific sign of axial spondyloarthritis seen on MRI. Joint Bone Spine 83(2):179–183PubMedCrossRef
247.
Wick MC et al (2010) Erosions are the most relevant magnetic resonance imaging features in quantification of sacroiliac joints in ankylosing spondylitis. J Rheumatol 37(3):622–627PubMedCrossRef
248.
Weber U et al (2013) Development and validation of a magnetic resonance imaging reference criterion for defining a positive sacroiliac joint magnetic resonance imaging finding in spondyloarthritis. Arthritis Care Res (hoboken) 65(6):977–985CrossRef
249.
Weber U et al (2010) The diagnostic utility of magnetic resonance imaging in spondylarthritis: an international multicenter evaluation of one hundred eighty-seven subjects. Arthritis Rheum 62(10):3048–3058PubMedCrossRef
250.
Weber U et al (2010) Assessment of structural lesions in sacroiliac joints enhances diagnostic utility of magnetic resonance imaging in early spondylarthritis. Arthritis Care Res (hoboken) 62(12):1763–1771CrossRef
251.
Madsen KB, Schiottz-Christensen B, Jurik AG (2010) Prognostic significance of magnetic resonance imaging changes of the sacroiliac joints in spondyloarthritis—a followup study. J Rheumatol 37(8):1718–1727PubMedCrossRef
252.
Bennett AN et al (2008) Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum 58(11):3413–3418PubMedCrossRef
253.
Pedersen SJ et al (2016) Course of magnetic resonance imaging-detected inflammation and structural lesions in the sacroiliac joints of patients in the randomized, double-blind, placebo-controlled Danish Multicenter study of Adalimumab in Spondyloarthritis, as assessed by the berlin and Spondyloarthritis research consortium of Canada methods. Arthritis Rheumatol 68(2):418–429PubMedCrossRef
254.
Baraliakos X et al (2005) Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Ann Rheum Dis 64(5):730–734PubMedCrossRef
255.
Rennie WJ et al (2009) Magnetic resonance imaging assessment of spinal inflammation in ankylosing spondylitis: standard clinical protocols may omit inflammatory lesions in thoracic vertebrae. Arthritis Rheum 61(9):1187–1193PubMedCrossRef
256.
Appel H et al (2006) Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Arthritis Res Ther 8(5):R143PubMedPubMedCentralCrossRef
257.
Jevtic V et al (2000) Marginal erosive discovertebral “Romanus” lesions in ankylosing spondylitis demonstrated by contrast enhanced Gd-DTPA magnetic resonance imaging. Skeletal Radiol 29(1):27–33PubMedCrossRef
258.
Romanus R, Yden S (1952) Destructive and ossifying spondylitic changes in rheumatoid ankylosing spondylitis (pelvo-spondylitis ossificans). Acta Orthop Scand 22(2):88–99PubMedCrossRef
259.
Bennett AN et al (2009) Evaluation of the diagnostic utility of spinal magnetic resonance imaging in axial spondylarthritis. Arthritis Rheum 60(5):1331–1341PubMedCrossRef
260.
Kenny JB, Hughes PL, Whitehouse GH (1990) Discovertebral destruction in ankylosing spondylitis: the role of computed tomography and magnetic resonance imaging. Br J Radiol 63(750):448–455PubMedCrossRef
261.
Kabasakal Y, Garrett SL, Calin A (1996) The epidemiology of spondylodiscitis in ankylosing spondylitis—a controlled study. Br J Rheumatol 35(7):660–663PubMedCrossRef
262.
Bennett AN et al (2010) The fatty Romanus lesion: a non-inflammatory spinal MRI lesion specific for axial spondyloarthropathy. Ann Rheum Dis 69(5):891–894PubMedCrossRef
263.
Braun J et al (2004) Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis 63(9):1046–1055PubMedPubMedCentralCrossRef
264.
Braun J et al (2003) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 48(4):1126–1136PubMedCrossRef
265.
van der Heijde D et al (2007) Is there a preferred method for scoring activity of the spine by magnetic resonance imaging in ankylosing spondylitis? J Rheumatol 34(4):871–873PubMed
266.
Maksymowych WP et al (2005) Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum 53(5):703–709PubMedCrossRef
267.
Maksymowych WP et al (2007) Validation of the spondyloarthritis research consortium of Canada magnetic resonance imaging spinal inflammation index: is it necessary to score the entire spine? Arthritis Rheum 57(3):501–507PubMedCrossRef
268.
Lukas C et al (2007) Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. J Rheumatol 34(4):862–870PubMed
269.
Treitl M et al (2008) Magnetic resonance imaging assessment of spinal inflammation in patients treated for ankylosing spondylitis. J Rheumatol 35(1):126–136PubMed
270.
Kiltz U et al (2012) The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: a cohort study. Ann Rheum Dis 71(7):1207–1211PubMedCrossRef
271.
Madsen KB, Jurik AG (2010) MRI grading method for active and chronic spinal changes in spondyloarthritis. Clin Radiol 65(1):6–14PubMedCrossRef
272.
Weber U et al (2015) Does spinal MRI add incremental diagnostic value to MRI of the sacroiliac joints alone in patients with non-radiographic axial spondyloarthritis? Ann Rheum Dis 74(6):985–992PubMedCrossRef
273.
Hermann KG et al (2012) Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. Ann Rheum Dis 71(8):1278–1288PubMedCrossRef
274.
Rudwaleit M et al (2008) MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 67(9):1276–1281PubMedCrossRef
275.
Braun J et al (2006) Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 54(5):1646–1652PubMedCrossRef
276.
Baraliakos X et al (2005) Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 53(6):856–863PubMedCrossRef
277.
Baraliakos X et al (2005) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 52(4):1216–1223PubMedCrossRef
278.
Sieper J et al (2005) Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatol (oxford) 44(12):1525–1530CrossRef
279.
Jarrett SJ et al (2009) MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib. Ann Rheum Dis 68(9):1466–1469PubMedCrossRef
280.
Feydy A et al (2012) Comparative study of MRI and power Doppler ultrasonography of the heel in patients with spondyloarthritis with and without heel pain and in controls. Ann Rheum Dis 71(4):498–503PubMedCrossRef
281.
Spadaro A et al (2009) Sonographic-detected joint effusion compared with physical examination in the assessment of sacroiliac joints in spondyloarthritis. Ann Rheum Dis 68(10):1559–1563PubMedCrossRef
282.
Unlu E, Pamuk ON, Cakir N (2007) Color and duplex Doppler sonography to detect sacroiliitis and spinal inflammation in ankylosing spondylitis. Can this method reveal response to anti-tumor necrosis factor therapy? J Rheumatol 34(1):110–116PubMed
283.
Aydin SZ et al (2010) Validation of ultrasound imaging for Achilles entheseal fibrocartilage in bovines and description of changes in humans with spondyloarthritis. Ann Rheum Dis 69(12):2165–2168PubMedCrossRef
284.
D’Agostino MA et al (2011) How to diagnose spondyloarthritis early? Accuracy of peripheral enthesitis detection by power Doppler ultrasonography. Ann Rheum Dis 70(8):1433–1440PubMedCrossRef
285.
de Miguel E et al (2011) Diagnostic accuracy of enthesis ultrasound in the diagnosis of early spondyloarthritis. Ann Rheum Dis 70(3):434–439PubMedCrossRef
286.
de Miguel E et al (2009) Validity of enthesis ultrasound assessment in spondyloarthropathy. Ann Rheum Dis 68(2):169–174PubMedCrossRef
287.
Ruyssen-Witrand A et al (2017) Relationships between ultrasound enthesitis, disease activity and axial radiographic structural changes in patients with early spondyloarthritis: data from DESIR cohort. RMD Open 3(2):e482PubMedPubMedCentralCrossRef
288.
Song IH et al (2008) The diagnostic value of scintigraphy in assessing sacroiliitis in ankylosing spondylitis: a systematic literature research. Ann Rheum Dis 67(11):1535–1540PubMedCrossRef
289.
Song IH et al (2010) Limited diagnostic value of unilateral sacroiliitis in scintigraphy in assessing axial spondyloarthritis. J Rheumatol 37(6):1200–1202PubMedCrossRef
290.
Devauchelle-Pensec V et al (2012) Computed tomography scanning facilitates the diagnosis of sacroiliitis in patients with suspected spondylarthritis: results of a prospective multicenter French cohort study. Arthritis Rheum 64(5):1412–1419PubMedCrossRef
291.
Strobel K et al (2010) 18F-fluoride PET/CT for detection of sacroiliitis in ankylosing spondylitis. Eur J Nucl Med Mol Imaging 37(9):1760–1765PubMedCrossRef
292.
Dougados M et al (1999) Clinical relevance of C‑reactive protein in axial involvement of ankylosing spondylitis. J Rheumatol 26(4):971–974PubMed
293.
Benhamou M, Gossec L, Dougados M (2010) Clinical relevance of C‑reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs’ treatment effect on C‑reactive protein. Rheumatol (oxford) 49(3):536–541CrossRef
294.
Kroon F et al (2012) Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 71(10):1623–1629PubMedCrossRef
295.
Poddubnyy D et al (2012) Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 71(10):1616–1622PubMedCrossRef
296.
Poddubnyy DA et al (2010) Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis 69(7):1338–1341PubMedCrossRef
297.
de Vries MK et al (2009) Erythrocyte sedimentation rate, C‑reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 61(11):1484–1490PubMedCrossRef
298.
Klingberg E et al (2017) A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Arthritis Res Ther 19(1):21PubMedPubMedCentralCrossRef
299.
Cypers H et al (2016) Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Ann Rheum Dis 75(7):1357–1362PubMedCrossRef
300.
van der Heijde D et al (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68(12):1811–1818PubMedCrossRef
301.
Brandt J et al (2003) Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany. Z Rheumatol 62(3):264–273PubMed
302.
Pavy S, Brophy S, Calin A (2005) Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study. J Rheumatol 32(1):80–85PubMed
303.
Brandt J et al (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43(6):1346–1352PubMedCrossRef
304.
Berthelot JM et al (2008) High intraindividual week-to-week variability in BASDAI and BASFI values: are several evaluations needed before starting or stopping TNFalpha antagonist therapy for spondyloarthropathies? Joint Bone Spine 75(2):167–171PubMedCrossRef
305.
Song IH et al (2009) Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. Ann Rheum Dis 68(11):1701–1707PubMedCrossRef
306.
Machado P et al (2015) Calculating the ankylosing spondylitis disease activity score if the conventional c‑reactive protein level is below the limit of detection or if high-sensitivity c‑reactive protein is used: an analysis in the DESIR cohort. Arthritis Rheumatol 67(2):408–413PubMedCrossRef
307.
Machado P et al (2011) Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70(1):47–53PubMedCrossRef
308.
Nas K et al (2010) Discrimination ability of ASDAS estimating disease activity status in patients with ankylosing spondylitis. Int J Rheum Dis 13(3):240–245PubMedCrossRef
309.
Pedersen SJ et al (2010) Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 69(6):1065–1071PubMedCrossRef
310.
Aydin SZ et al (2010) Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis. Clin Exp Rheumatol 28(5):752–755PubMed
311.
Vastesaeger N et al (2014) ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy. Reumatol Clin 10(4):204–209PubMedCrossRef
312.
Kilic E et al (2015) Discriminant validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: a cohort study. Rheumatol Int 35(6):981–989PubMedCrossRef
313.
Kilic G, Kilic E, Ozgocmen S (2017) Is there any gender-specific difference in the cut-off values of ankylosing spondylitis disease activity score in patients with axial spondyloarthritis? Int J Rheum Dis 20(9):1201–1211PubMedCrossRef
314.
Huscher D et al (2015) Trends in treatment and outcomes of ankylosing spondylitis in outpatient rheumatological care in Germany between 2000 and 2012. RMD Open 1(1):e33PubMedPubMedCentralCrossRef
315.
Doran MF et al (2003) Predictors of longterm outcome in ankylosing spondylitis. J Rheumatol 30(2):316–320PubMed
316.
Amor B et al (1994) Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol 21(10):1883–1887PubMed
317.
Gran JT, Skomsvoll JF (1997) The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 36(7):766–771PubMedCrossRef
318.
Averns HL et al (1996) Smoking and outcome in ankylosing spondylitis. Scand J Rheumatol 25(3):138–142PubMedCrossRef
319.
Ward MM (2002) Predictors of the progression of functional disability in patients with ankylosing spondylitis. J Rheumatol 29(7):1420–1425PubMed
320.
Brophy S et al (2002) The natural history of ankylosing spondylitis as defined by radiological progression. J Rheumatol 29(6):1236–1243PubMed
321.
van der Heijde D et al (1997) Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 24(11):2225–2229PubMed
322.
van der Heijde D et al (1999) Ankylosing spondylitis: plenary discussion and results of voting on selection of domains and some specific instruments. J Rheumatol 26(4):1003–1005PubMed
323.
Anderson JJ et al (2001) Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44(8):1876–1886PubMedCrossRef
324.
Sieper J et al (2012) Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis 71(5):700–706PubMedCrossRef
325.
Rudwaleit M et al (2010) Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther 12(3):R117PubMedPubMedCentralCrossRef
326.
Glintborg B et al (2010) Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years’ surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 69(11):2002–2008PubMedCrossRef
327.
Lord PA et al (2010) Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatol (oxford) 49(3):563–570CrossRef
328.
Perrotta FM et al (2014) Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFalpha drugs. Reumatismo 66(3):208–214PubMedCrossRef
329.
Rausch Osthoff AK et al (2018) EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheum Dis 77(9):1251–1260PubMedCrossRef
330.
Klemz BN et al (2016) The relevance of performing exercise test before starting supervised physical exercise in asymptomatic cardiovascular patients with rheumatic diseases. Rheumatol (oxford) 55(11):1978–1986CrossRef
331.
Dagfinrud H, Kvien TK, Hagen KB (2008) Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev 2008(1):CD2822PubMedCentral
332.
van Tubergen A et al (2001) Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 45(5):430–438PubMedCrossRef
333.
Escalas C et al (2016) Evaluation of physiotherapy in a prospective cohort of early axial spondyloarthritis. Data from the DESIR cohort. Joint Bone Spine 83(2):185–190PubMedCrossRef
334.
Albrecht K, Huscher D (2017) Do we prescribe physical medicine sufficiently? Current data from the German Collaborative Arthritis Center. Akt Rheumatol 42:118–121CrossRef
335.
Martins NA et al (2014) Exercise and ankylosing spondylitis with New York modified criteria: a systematic review of controlled trials with meta-analysis. Acta Reumatol Port 39(4):298–308PubMed
336.
Sharan D, Rajkumar JS (2017) Physiotherapy for Ankylosing Spondylitis: systematic review and a proposed rehabilitation protocol. Curr Rheumatol Rev 13(2):121–125PubMedCrossRef
337.
Jennings F et al (2015) Effects of aerobic training in patients with Ankylosing Spondylitis. J Rheumatol 42(12):2347–2353PubMedCrossRef
338.
Liang H et al (2015) Effects of home-based exercise intervention on health-related quality of life for patients with ankylosing spondylitis: a meta-analysis. Clin Rheumatol 34(10):1737–1744PubMedCrossRef
339.
Niedermann K et al (2013) Effect of cardiovascular training on fitness and perceived disease activity in people with ankylosing spondylitis. Arthritis Care Res (hoboken) 65(11):1844–1852CrossRef
340.
Rosu MO et al (2014) Effects of Pilates, McKenzie and Heckscher training on disease activity, spinal motility and pulmonary function in patients with ankylosing spondylitis: a randomized controlled trial. Rheumatol Int 34(3):367–372PubMedCrossRef
341.
Altan L et al (2012) Effect of Pilates training on people with ankylosing spondylitis. Rheumatol Int 32(7):2093–2099PubMedCrossRef
342.
Passalent LA et al (2010) Exercise in ankylosing spondylitis: discrepancies between recommendations and reality. J Rheumatol 37(4):835–841PubMedCrossRef
343.
Fongen C, Halvorsen S, Dagfinrud H (2013) High disease activity is related to low levels of physical activity in patients with ankylosing spondylitis. Clin Rheumatol 32(12):1719–1725PubMedCrossRef
344.
Kjeken I et al (2013) A three-week multidisciplinary in-patient rehabilitation programme had positive long-term effects in patients with ankylosing spondylitis: randomized controlled trial. J Rehabil Med 45(3):260–267PubMedCrossRef
345.
Masiero S et al (2014) Supervised training and home-based rehabilitation in patients with stabilized ankylosing spondylitis on TNF inhibitor treatment: a controlled clinical trial with a 12-month follow-up. Clin Rehabil 28(6):562–572PubMedCrossRef
346.
Durmus D et al (2009) Effects of a home-based exercise program on quality of life, fatigue, and depression in patients with ankylosing spondylitis. Rheumatol Int 29(6):673–677PubMedCrossRef
347.
Durmus D et al (2009) Effects of two exercise interventions on pulmonary functions in the patients with ankylosing spondylitis. Joint Bone Spine 76(2):150–155PubMedCrossRef
348.
Karapolat H et al (2009) Are swimming or aerobic exercise better than conventional exercise in ankylosing spondylitis patients? A randomized controlled study. Eur J Phys Rehabil Med 45(4):449–457PubMed
349.
Widberg K, Karimi H, Hafstrom I (2009) Self- and manual mobilization improves spine mobility in men with ankylosing spondylitis—a randomized study. Clin Rehabil 23(7):599–608PubMedCrossRef
350.
Aytekin E et al (2012) Home-based exercise therapy in patients with ankylosing spondylitis: effects on pain, mobility, disease activity, quality of life, and respiratory functions. Clin Rheumatol 31(1):91–97PubMedCrossRef
351.
Colina M et al (2009) Combination treatment with etanercept and an intensive spa rehabilitation program in active ankylosing spondylitis. Int J Immunopathol Pharmacol 22(4):1125–1129PubMedCrossRef
352.
Karahan AY et al (2016) The effectiveness of Exergames in patients with Ankylosing Spondylitis: a randomized controlled trial. Adv Clin Exp Med 25(5):931–936PubMedCrossRef
353.
Kraag G et al (1990) The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis—a randomized controlled trial. J Rheumatol 17(2):228–233PubMed
354.
Ince G et al (2006) Effects of a multimodal exercise program for people with ankylosing spondylitis. Phys Ther 86(7):924–935PubMed
355.
Lim HJ, Moon YI, Lee MS (2005) Effects of home-based daily exercise therapy on joint mobility, daily activity, pain, and depression in patients with ankylosing spondylitis. Rheumatol Int 25(3):225–229PubMedCrossRef
356.
Kraag G et al (1994) The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis—an 8‑month followup. J Rheumatol 21(2):261–263PubMed
357.
Karapolat H et al (2008) Comparison of group-based exercise versus home-based exercise in patients with ankylosing spondylitis: effects on Bath Ankylosing Spondylitis Indices, quality of life and depression. Clin Rheumatol 27(6):695–700PubMedCrossRef
358.
Hidding A et al (1993) Is group physical therapy superior to individualized therapy in ankylosing spondylitis? A randomized controlled trial. Arthritis Care Res 6(3):117–125PubMedCrossRef
359.
Helliwell P (1996) A randomised trial of three different physiotherapy regimes in ankylosing spondylitis. Physiotherapy 82:85–90CrossRef
360.
Analay Y et al (2003) The effectiveness of intensive group exercise on patients with ankylosing spondylitis. Clin Rehabil 17(6):631–636PubMedCrossRef
361.
Bakker C et al (1994) Cost effectiveness of group physical therapy compared to individualized therapy for ankylosing spondylitis. A randomized controlled trial. J Rheumatol 21(2):264–268PubMed
362.
Ciprian L et al (2013) The effects of combined spa therapy and rehabilitation on patients with ankylosing spondylitis being treated with TNF inhibitors. Rheumatol Int 33(1):241–245PubMedCrossRef
363.
Gurcay E et al (2008) Stanger bath therapy for ankylosing spondylitis: illusion or reality? Clin Rheumatol 27(7):913–917PubMedCrossRef
364.
Altan L et al (2006) The effect of balneotherapy on patients with ankylosing spondylitis. Scand J Rheumatol 35(4):283–289PubMedCrossRef
365.
Codish S et al (2005) Spa therapy for ankylosing spondylltis at the Dead Sea. Isr Med Assoc J 7(7):443–446PubMed
366.
Rutherford SM, Nicolson CF, Crowther ER (2005) Symptomatic improvement in function and disease activity in a patient with ankylosing spondylitis utilizing a course of chiropractic therapy: a prospective case study. J Can Chiropr Assoc 49(2):81–91PubMedPubMedCentral
367.
Oosterveld FG et al (2009) Infrared sauna in patients with rheumatoid arthritis and ankylosing spondylitis. A pilot study showing good tolerance, short-term improvement of pain and stiffness, and a trend towards long-term beneficial effects. Clin Rheumatol 28(1):29–34PubMedCrossRef
368.
Tarner IH et al (2009) The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis. Clin Rheumatol 28(4):397–402PubMedCrossRef
369.
Samborski W et al (1992) Can thermal therapy of ankylosing spondylitis induce an activation of the disease? Z Rheumatol 51(3):127–131PubMed
370.
Gemignani G et al (1991) Transcutaneous electrical nerve stimulation in ankylosing spondylitis: a double-blind study. Arthritis Rheum 34(6):788–789PubMedCrossRef
371.
Turan Y et al (2014) Is magnetotherapy applied to bilateral hips effective in ankylosing spondylitis patients? A randomized, double-blind, controlled study. Rheumatol Int 34(3):357–365PubMedCrossRef
372.
Silte Karamanlioglu D et al (2016) Effectiveness of ultrasound treatment applied with exercise therapy on patients with ankylosing spondylitis: a double-blind, randomized, placebo-controlled trial. Rheumatol Int 36(5):653–661PubMedCrossRef
373.
Spadaro A et al (2008) Occupational therapy in ankylosing spondylitis: Short-term prospective study in patients treated with anti-TNF-alpha drugs. Joint Bone Spine 75(1):29–33PubMedCrossRef
374.
Barkhuizen A et al (2006) Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. J Rheumatol 33(9):1805–1812PubMed
375.
Dougados M et al (1989) A double blind crossover placebo controlled trial of ximoprofen in as. J Rheumatol 16(8):1167–1169PubMed
376.
Dougados M et al (1994) Ximoprofen in ankylosing spondylitis. A double blind placebo controlled dose ranging study. Scand J Rheumatol 23(5):243–248PubMedCrossRef
377.
Sturrock RD, Hart FD (1974) Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis. Ann Rheum Dis 33(2):129–131PubMedPubMedCentralCrossRef
378.
van der Heijde D et al (2005) Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 52(4):1205–1215PubMedCrossRef
379.
Kroon FP et al (2016) Nonsteroidal antiinflammatory drugs for axial Spondyloarthritis: a Cochrane review. J Rheumatol 43(3):607–617PubMedCrossRef
380.
Wang R, Dasgupta A, Ward MM (2016) Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials. Ann Rheum Dis 75(6):1152–1160PubMedCrossRef
381.
Sieper J et al (2014) Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis 73(1):101–107PubMedCrossRef
382.
Gossec L et al (2005) Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 64(11):1563–1567PubMedPubMedCentralCrossRef
383.
Sieper J et al (2008) Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis 67(3):323–329PubMedCrossRef
384.
Escalas C, Trijau S, Dougados M (2010) Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis. Rheumatol (oxford) 49(7):1317–1325CrossRef
385.
Walker C et al (2016) Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients. J Int Med Res 44(3):483–495PubMedPubMedCentralCrossRef
386.
Balazcs E et al (2016) A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis. Bmc Musculoskelet Disord 17(1):426PubMedPubMedCentralCrossRef
387.
Peloso PM et al (2011) Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis. Bmc Musculoskelet Disord 12:165PubMedPubMedCentralCrossRef
388.
Dougados M et al (2014) Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study. Arthritis Res Ther 16(6):481PubMedPubMedCentralCrossRef
389.
van der Heijde D et al (2011) 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 70(6):905–908PubMedCrossRef
390.
Zochling J et al (2006) Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis—a population-based survey. Clin Rheumatol 25(6):794–800PubMedCrossRef
391.
Wanders A et al (2005) Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 52(6):1756–1765PubMedCrossRef
392.
Sieper J et al (2016) Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis 75(8):1438–1443PubMedCrossRef
393.
Colebatch AN, Marks JL, Edwards CJ (2011) Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev 2011(11):CD8872
394.
Kristensen LE et al (2015) Safety of Etoricoxib, Celecoxib, and nonselective Nonsteroidal antiinflammatory drugs in Ankylosing Spondylitis and other Spondyloarthritis patients: a Swedish national population-based cohort study. Arthritis Care Res (hoboken) 67(8):1137–1149CrossRef
395.
Cannon CP et al (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368(9549):1771–1781PubMedCrossRef
396.
Farkouh ME et al (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364(9435):675–684PubMedCrossRef
397.
Song IH et al (2008) Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum 58(4):929–938PubMedCrossRef
398.
Bally M et al (2017) Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 357:j1909PubMedPubMedCentralCrossRef
399.
Fanelli A et al (2017) Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Ther Adv Drug Saf 8(6):173–182PubMedPubMedCentralCrossRef
400.
401.
Burmester G et al (2011) The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis 70(5):818–822PubMedCrossRef
402.
Arzneimittelkommission der deutschen Ärzteschaft (2008) Empfehlungen zur Therapie von degenerativen Gelenkerkrankungen. 35(Sonderheft 1)
403.
Lanza FL et al (2009) Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 104(3):728–738PubMed
404.
Yokoyama H et al (2013) Influence of non-steroidal anti-inflammatory drugs on antiplatelet effect of aspirin. J Clin Pharm Ther 38(1):12–15PubMedCrossRef
405.
Catella-Lawson F et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345(25):1809–1817PubMedCrossRef
406.
Zhang X et al (2017) Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. Bmc Nephrol 18(1):256PubMedPubMedCentralCrossRef
407.
Gooch K et al (2007) NSAID use and progression of chronic kidney disease. Am J Med 120(3):280 e1–280 e7CrossRef
408.
Basavaraj KH et al (2010) The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol 49(12):1351–1361PubMedCrossRef
409.
Gossec L et al (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75(3):499–510PubMedCrossRef
410.
Canoui-Poitrine F et al (2014) Early tumor necrosis factor alpha antagonist therapy in everyday practice for inflammatory back pain suggesting axial spondyloarthritis: results from a prospective multicenter french cohort. Arthritis Care Res (hoboken) 66(9):1395–1402CrossRef
411.
Chen C et al (2016) Comparative effectiveness of biologic therapy regimens for Ankylosing Spondylitis: a systematic review and a network Meta-analysis. Medicine (Baltimore) 95(11):e3060CrossRef
412.
Betts KA et al (2016) Network Meta-analysis and cost Per responder of tumor necrosis factor-alpha and Interleukin inhibitors in the treatment of active Ankylosing Spondylitis. Rheumatol Ther 3(2):323–336PubMedPubMedCentralCrossRef
413.
Callhoff J et al (2015) Efficacy of TNFalpha blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis 74(6):1241–1248PubMedCrossRef
414.
Li ZH et al (2013) Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population. Eur J Orthop Surg Traumatol 23(5):497–506PubMedCrossRef
415.
Wang H et al (2014) Randomized, placebo controlled and double-blind trials of efficacy and safety of adalimumab for treating ankylosing spondylitis: a meta-analysis. Int J Rheum Dis 17(2):142–148PubMedCrossRef
416.
Wang Y et al (2016) Comparative efficacy and acceptability of anti-TNF-Alpha therapy in Ankylosing Spondylitis: a mixed-treatments comparison. Cell Physiol Biochem 39(5):1679–1694PubMedCrossRef
417.
Braun J et al (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38(4):499–505PubMedCrossRef
418.
Zochling J et al (2006) Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 65(4):423–432PubMedCrossRef
419.
Sepriano A et al (2017) Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open 3(1):e396PubMedPubMedCentralCrossRef
420.
Maxwell LJ et al (2015) TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev 2015(4):CD5468
421.
Olivieri I et al (2016) Efficacy, safety and cost per responder of biologics in the treatment of non-radiographic axial spondyloarthritis. Clin Exp Rheumatol 34(5):935–940PubMed
422.
Ren L et al (2013) Efficacy of antitumor necrosis factor(alpha) agents on patients with ankylosing spondylitis. Am J Med Sci 346(6):455–461PubMedCrossRef
423.
van der Heijde D et al (2008) Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis 67(9):1218–1221PubMedCrossRef
424.
Dougados M et al (2011) Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis 70(5):799–804PubMedCrossRef
425.
Haibel H et al (2008) Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 58(7):1981–1991PubMedCrossRef
426.
Song IH et al (2011) Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 70(4):590–596PubMedCrossRef
427.
Barkham N et al (2009) Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 60(4):946–954PubMedCrossRef
428.
Sieper J et al (2013) Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 72(6):815–822PubMedCrossRef
429.
Corbett M et al (2016) Tumour necrosis factor-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technol Assess 20(9):1–334PubMedPubMedCentralCrossRef
430.
Ciurea A et al (2013) Tumor necrosis factor alpha inhibition in radiographic and Nonradiographic axial Spondyloarthritis: results from a large observational cohort. Arthritis Rheum 65(12):3096–3106PubMedCrossRef
431.
Corli J et al (2015) Tumor necrosis factor-alpha inhibition in Ankylosing Spondylitis and Nonradiographic axial Spondyloarthritis: treatment response, drug survival, and patient outcome. J Rheumatol 42(12):2376–2382PubMedCrossRef
432.
Kristensen LE et al (2010) Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res (hoboken) 62(10):1362–1369CrossRef
433.
Arends S et al (2011) Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 13(3):R94PubMedPubMedCentralCrossRef
434.
Vastesaeger N et al (2011) Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 70(6):973–981PubMedCrossRef
435.
Maneiro JR et al (2015) Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open 1(1):e17PubMedPubMedCentralCrossRef
436.
van der Heijde D et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54(7):2136–2146PubMedCrossRef
437.
van der Heijde D et al (2009) Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 68(6):922–929PubMedCrossRef
438.
Davis JC Jr. et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48(11):3230–3236PubMedCrossRef
439.
Davis JC et al (2005) Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 64(11):1557–1562PubMedPubMedCentralCrossRef
440.
Davis JC Jr. et al (2008) Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 67(3):346–352PubMedCrossRef
441.
Calin A et al (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63(12):1594–1600PubMedPubMedCentralCrossRef
442.
Dijkmans B et al (2009) Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 36(6):1256–1264PubMedCrossRef
443.
Martin-Mola E et al (2010) Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol 28(2):238–245PubMed
444.
van der Heijde D et al (2006) Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 65(12):1572–1577PubMedPubMedCentralCrossRef
445.
Dougados M et al (2010) A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Ann Rheum Dis 69(8):1430–1435PubMedCrossRef
446.
Navarro-Sarabia F et al (2011) High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). Rheumatol (oxford) 50(10):1828–1837CrossRef
447.
Braun J et al (2011) Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 63(6):1543–1551PubMedCrossRef
448.
Inman RD et al (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58(11):3402–3412PubMedCrossRef
449.
Braun J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359(9313):1187–1193PubMedCrossRef
450.
Braun J et al (2005) Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 64(2):229–234PubMedCrossRef
451.
Braun J et al (2005) Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatol (oxford) 44(5):670–676CrossRef
452.
Braun J et al (2008) Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 67(3):340–345PubMedCrossRef
453.
Baraliakos X et al (2011) Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years—early clinical response predicts long-term outcome. Rheumatol (oxford) 50(9):1690–1699CrossRef
454.
van der Heijde D et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52(2):582–591PubMedCrossRef
455.
Heldmann F et al (2011) The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 29(4):672–680PubMed
456.
Bao C et al (2014) Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1‑year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial. Rheumatol (oxford) 53(9):1654–1663CrossRef
457.
Deodhar A et al (2018) Safety and efficacy of Golimumab administered intravenously in adults with Ankylosing Spondylitis: results through week 28 of the GO-ALIVE study. J Rheumatol 45(3):341–348PubMedCrossRef
458.
Dougados M et al (2014) Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 66(8):2091–2102PubMedCrossRef
459.
Huang F et al (2014) Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial. Ann Rheum Dis 73(3):587–594PubMedCrossRef
460.
Landewe R et al (2014) Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 73(1):39–47PubMedCrossRef
461.
Park W et al (2013) A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 72(10):1605–1612PubMedCrossRef
462.
Cohen JD et al (2007) Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol 34(2):380–385PubMed
463.
Davis JC Jr. et al (2007) Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum 57(6):1050–1057PubMedCrossRef
464.
Braun J et al (2007) Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatol (oxford) 46(6):999–1004CrossRef
465.
Boonen A et al (2008) Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept. J Rheumatol 35(4):662–667PubMed
466.
Kimel M et al (2011) Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis. Clin Exp Rheumatol 29(4):624–632PubMed
467.
Braun J et al (2009) Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab. Arthritis Rheum 61(8):1032–1036PubMedCrossRef
468.
Gonnet-Gracia C et al (2008) Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. Clin Exp Rheumatol 26(3):401–407PubMed
469.
Maksymowych WP et al (2010) Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study. J Rheumatol 37(8):1728–1734PubMedCrossRef
470.
van der Heijde D et al (2008) Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 58(5):1324–1331PubMedCrossRef
471.
Baraliakos X et al (2007) Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatol (oxford) 46(9):1450–1453CrossRef
472.
Haroon N et al (2013) The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 65(10):2645–2654PubMedPubMedCentral
473.
Kim TJ et al (2016) Radiographic progression in patients with ankylosing spondylitis according to tumor necrosis factor blocker exposure: Observation Study of Korean Spondyloarthropathy Registry (OSKAR) data. Joint Bone Spine 83(5):569–572PubMedCrossRef
474.
Maas F et al (2017) Reduction in spinal radiographic progression in Ankylosing Spondylitis patients receiving prolonged treatment with tumor necrosis factor inhibitors. Arthritis Care Res (hoboken) 69(7):1011–1019CrossRef
475.
Molnar C et al (2018) TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis 77(1):63–69PubMedCrossRef
476.
Park JW et al (2016) Impact of dose tapering of tumor necrosis factor inhibitor on radiographic progression in Ankylosing Spondylitis. PLoS ONE 11(12):e168958PubMedPubMedCentralCrossRef
477.
Visvanathan S et al (2009) Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 68(2):175–182PubMedCrossRef
478.
Siu S et al (2015) Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials. Arthritis Care Res (hoboken) 67(6):754–764CrossRef
479.
van der Heijde D et al (2006) Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Rheum 55(4):569–574PubMedCrossRef
480.
Barkham N et al (2010) Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis 69(11):1926–1928PubMedCrossRef
481.
Keat AC et al (2008) Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis. Rheumatol (oxford) 47(4):481–483CrossRef
482.
Kristensen LE et al (2012) Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study. Rheumatology (Oxford) 51(2):243–249CrossRef
483.
Maksymowych WP et al (2010) Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. J Rheumatol 37(2):385–392PubMedCrossRef
484.
Wallman JK et al (2017) Work disability in non-radiographic axial spondyloarthritis patients before and after start of anti-TNF therapy: a population-based regional cohort study from southern Sweden. Rheumatology (Oxford) 56(5):716–724
485.
Baeten D et al (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382(9906):1705–1713PubMedCrossRef
486.
Baeten D et al (2015) Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med 373(26):2534–2548PubMedCrossRef
487.
Sieper J et al (2017) Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis 76(3):571–592PubMedCrossRef
488.
Pavelka K et al (2017) Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther 19(1):285PubMedPubMedCentralCrossRef
489.
Deodhar AA et al (2016) Effect of Secukinumab on patient-reported outcomes in patients with active Ankylosing Spondylitis: a phase III randomized trial (MEASURE 1). Arthritis Rheumatol 68(12):2901–2910PubMedPubMedCentralCrossRef
490.
Deodhar A et al (2019) Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C‑reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2‑year data from the MEASURE 2 study. Clin Exp Rheumatol 37(2):260–269PubMed
491.
Baraliakos X et al (2016) Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Ann Rheum Dis 75(2):408–412PubMedCrossRef
492.
Baraliakos X et al (2018) Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3‑year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. Clin Exp Rheumatol 36(1):50–55PubMed
493.
Braun J et al (2017) Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2‑year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 76(6):1070–1077PubMedCrossRef
494.
Marzo-Ortega H et al (2017) Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3‑year results from the phase III trial, MEASURE 2. RMD Open 3(2):e592PubMedPubMedCentralCrossRef
495.
Song IH et al (2010) Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 62(5):1290–1297PubMedCrossRef
496.
Song IH et al (2011) Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 70(6):1108–1110PubMedCrossRef
497.
Sieper J et al (2015) Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis 74(6):1051–1057PubMedCrossRef
498.
Sieper J et al (2014) Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 73(19):95–100PubMedCrossRef
499.
Poddubnyy D et al (2014) Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 73(5):817–823PubMedCrossRef
500.
Deodhar A et al (2019) Three Multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of Ustekinumab in axial Spondyloarthritis. Arthritis Rheumatol 71(2):258–270PubMedCrossRef
501.
Heiberg MS et al (2008) The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 59(2):234–240PubMedCrossRef
502.
Glintborg B et al (2013) Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor alpha inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 72(7):1149–1155PubMedCrossRef
503.
Ciurea A et al (2016) Impaired response to treatment with tumour necrosis factor alpha inhibitors in smokers with axial spondyloarthritis. Ann Rheum Dis 75(3):532–539PubMedCrossRef
504.
Glintborg B et al (2016) Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Rheumatol (oxford) 55(4):659–668CrossRef
505.
Micheroli R et al (2017) Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis. Arthritis Res Ther 19(1):164PubMedPubMedCentralCrossRef
506.
Breban M et al (2008) Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 58(1):88–97PubMedCrossRef
507.
Marzo-Ortega H et al (2005) Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 64(11):1568–1575PubMedPubMedCentralCrossRef
508.
Li EK et al (2008) Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatol (oxford) 47(9):1358–1363CrossRef
509.
Perez-Guijo VC et al (2007) Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. Joint Bone Spine 74(3):254–258PubMedCrossRef
510.
Ma Z et al (2017) Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: a meta-analysis. Medicine (Baltimore) 96(25):e7145CrossRef
511.
Diel R et al (2009) Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases. Pneumologie 63(6):329–334PubMedCrossRef
512.
Fouque-Aubert A et al (2010) Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. Ann Rheum Dis 69(10):1756–1761PubMedCrossRef
513.
Xu Z et al (2017) Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: a meta-analysis of randomized controlled trials. Exp Ther Med 14(4):3491–3500PubMedPubMedCentralCrossRef
514.
Mariette X et al (2011) Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70(11):1895–1904PubMedCrossRef
515.
Baraliakos X et al (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7(3):R439–R444PubMedPubMedCentralCrossRef
516.
Landewe R et al (2018) Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet 392(10142):134–144PubMedCrossRef
517.
Sieper J et al (2014) Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. Ann Rheum Dis 73(1):108–113PubMedCrossRef
518.
Fong W et al (2016) The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis. Rheumatol (oxford) 55(10):1837–1842CrossRef
519.
Inman RD, Maksymowych WP (2010) A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol 37(6):1203–1210PubMedCrossRef
520.
Krzysiek R et al (2009) Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study. Arthritis Rheum 61(5):569–576PubMedCrossRef
521.
Arends S et al (2010) The formation of autoantibodies and antibodies to TNF-alpha blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 28(5):661–668PubMed
522.
de Vries MK et al (2007) Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 66(9):1252–1254PubMedPubMedCentralCrossRef
523.
de Vries MK et al (2009) Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 68(4):531–535PubMedCrossRef
524.
Lie E et al (2011) Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis 70(1):157–163PubMedCrossRef
525.
Ciurea A et al (2016) Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort. Arthritis Res Ther 18:71PubMedPubMedCentralCrossRef
526.
Navarro-Compan V et al (2017) Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review. RMD Open 3(2):e524PubMedPubMedCentralCrossRef
527.
Deodhar A, Yu D (2017) Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin Arthritis Rheum 47(3):343–350PubMedCrossRef
528.
Sepriano A et al (2016) Effect of Comedication with conventional synthetic disease-modifying Antirheumatic drugs on retention of tumor necrosis factor inhibitors in patients with Spondyloarthritis: a prospective cohort study. Arthritis Rheumatol 68(11):2671–2679PubMedCrossRef
529.
Nissen MJ et al (2016) The effect of Comedication with a conventional synthetic disease-modifying Antirheumatic drug on drug retention and clinical effectiveness of anti-tumor necrosis factor therapy in patients with axial Spondyloarthritis. Arthritis Rheumatol 68(9):2141–2150PubMedCrossRef
530.
Chen J, Liu C (2005) Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005(2):CD4800
531.
Chen J, Lin S, Liu C (2014) Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2014(11):CD4800
532.
Fagerli KM et al (2014) Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study. Rheumatol (oxford) 53(6):1087–1094CrossRef
533.
Genc H et al (2007) The effects of sulfasalazine treatment on enthesal abnormalities of inflammatory rheumatic diseases. Clin Rheumatol 26(7):1104–1110PubMedCrossRef
534.
Braun J et al (2006) Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 65(9):1147–1153PubMedPubMedCentralCrossRef
535.
Khanna Sharma S et al (2018) A randomized controlled trial to study the efficacy of sulfasalazine for axial disease in ankylosing spondylitis. Int J Rheum Dis 21(1):308–314PubMedCrossRef
536.
Liu YF et al (2014) Etanercept in the treatment of ankylosing spondylitis: a systematic review and meta-analysis. Exp Ther Med 8(5):1585–1592PubMedPubMedCentralCrossRef
537.
Deng X et al (2013) Thalidomide reduces recurrence of ankylosing spondylitis in patients following discontinuation of etanercept. Rheumatol Int 33(6):1409–1413PubMedCrossRef
538.
Chen J, Liu C, Lin J (2006) Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2006(4):CD4524
539.
Chen J et al (2013) Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev CD004524:2
540.
Haibel H et al (2014) Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. Ann Rheum Dis 73(1):243–246PubMedCrossRef
541.
Maksymowych WP et al (2002) A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 46(3):766–773PubMedCrossRef
542.
Haibel H et al (2003) Treatment of active ankylosing spondylitis with pamidronate. Rheumatol (oxford) 42(8):1018–1020CrossRef
543.
Cairns AP et al (2005) An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover. Ann Rheum Dis 64(2):338–339PubMedCrossRef
544.
Malaviya AN et al (2007) A new strategy of drug treatment in NSAID-unresponsive ankylosing spondylitis: combination of pamidronate and methylprednisolone monthly intravenous infusions on the background of a combination of disease modifying drugs sulfasalazine and methotrexate. J Assoc Physicians India 55:193–197PubMed
545.
Santra G et al (2010) Assessment of the efficacy of pamidronate in ankylosing spondylitis: an open prospective trial. Singapore Med J 51(11):883–887PubMed
546.
Coates L et al (2017) Clinical efficacy of oral alendronate in ankylosing spondylitis: a randomised placebo-controlled trial. Clin Exp Rheumatol 35(3):445–451PubMed
547.
Chatfield SM et al (2009) Complementary and alternative medicines in ankylosing spondylitis: a cross-sectional study. Clin Rheumatol 28(2):213–217PubMedCrossRef
548.
Brophy S et al (2008) Internet-based randomised controlled trials for the evaluation of complementary and alternative medicines: probiotics in spondyloarthropathy. Bmc Musculoskelet Disord 9:4PubMedPubMedCentralCrossRef
549.
Jenks K et al (2010) Probiotic therapy for the treatment of spondyloarthritis: a randomized controlled trial. J Rheumatol 37(10):2118–2125PubMedCrossRef
550.
Gotestam Skorpen C et al (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75(5):795–810PubMedCrossRef
551.
Flint J et al (2016) BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatol (oxford) 55(9):1693–1697CrossRef
552.
Villiger PM et al (2010) Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis 69(10):1842–1844PubMedCrossRef
553.
Verstappen SM et al (2011) Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70(5):823–826PubMedCrossRef
554.
Jakobsson GL et al (2016) Pregnancy outcomes in patients with ankylosing spondylitis: a nationwide register study. Ann Rheum Dis 75(10):1838–1842PubMedCrossRef
555.
van den Brandt S et al (2017) Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients. Arthritis Res Ther 19(1):64PubMedPubMedCentralCrossRef
556.
Mahendira D et al (2014) Analysis of the effect of the oral contraceptive pill on clinical outcomes in women with ankylosing spondylitis. J Rheumatol 41(7):1344–1348PubMedCrossRef
557.
Huang Z et al (2011) Efficacy and safety of ultrasound-guided local injections of etanercept into entheses of ankylosing spondylitis patients with refractory Achilles enthesitis. Clin Exp Rheumatol 29(4):642–649PubMed
558.
Maugars Y et al (1996) Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. Br J Rheumatol 35(8):767–770PubMedCrossRef
559.
Luukkainen R et al (1999) Periarticular corticosteroid treatment of the sacroiliac joint in patients with seronegative spondylarthropathy. Clin Exp Rheumatol 17(1):88–90PubMed
560.
Zheng Y et al (2014) Tomography-guided palisade sacroiliac joint radiofrequency neurotomy versus celecoxib for ankylosing spondylitis: a open-label, randomized, and controlled trial. Rheumatol Int 34(9):1195–1202PubMedCrossRef
561.
Braun J et al (1996) Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol 23(4):659–664PubMed
562.
Vander Cruyssen B et al (2010) Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. Rheumatol (oxford) 49(1):73–81CrossRef
563.
Lu MC et al (2017) Incident osteoarthritis and osteoarthritis-related joint replacement surgery in patients with ankylosing spondylitis: a secondary cohort analysis of a nationwide, population-based health claims database. PLoS ONE 12(11):e187594PubMedPubMedCentralCrossRef
564.
Bhan S, Eachempati KK, Malhotra R (2008) Primary cementless total hip arthroplasty for bony ankylosis in patients with ankylosing spondylitis. J Arthroplasty 23(6):859–866PubMedCrossRef
565.
Kiaer T, Gehrchen M (2010) Transpedicular closed wedge osteotomy in ankylosing spondylitis: results of surgical treatment and prospective outcome analysis. Eur Spine J 19(1):57–64PubMedCrossRef
566.
Regel A et al (2017) Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open 3(1):e397PubMedPubMedCentralCrossRef
567.
Pigge RR et al (2008) Effectiveness of preoperative planning in the restoration of balance and view in ankylosing spondylitis. Neurosurg Focus 24(1):E7PubMedCrossRef
568.
Anwar F et al (2011) Delayed presentation and diagnosis of cervical spine injuries in long-standing ankylosing spondylitis. Eur Spine J 20(3):403–407PubMedCrossRef
569.
Hoh DJ, Khoueir P, Wang MY (2008) Management of cervical deformity in ankylosing spondylitis. Neurosurg Focus 24(1):E9PubMedCrossRef
570.
571.
Thumbikat P et al (2007) Spinal cord injury in patients with ankylosing spondylitis: a 10-year review. Spine (phila Pa 1976) 32(26):2989–2995CrossRef
572.
Whang PG et al (2009) The management of spinal injuries in patients with ankylosing spondylitis or diffuse idiopathic skeletal hyperostosis: a comparison of treatment methods and clinical outcomes. J Spinal Disord Tech 22(2):77–85PubMedCrossRef
573.
574.
Ayhan F, Gecene M, Gündüz R (2011) Long-term effects of comprehensive inpatient rehabilitation on function and disease activity in patients with chronic rheumatoid arthritis and Ankylosing Spondylitis. Turk J Rheumatol 26:135–142CrossRef
575.
Staalesen Strumse YA et al (2011) Efficacy of rehabilitation for patients with ankylosing spondylitis: comparison of a four-week rehabilitation programme in a Mediterranean and a Norwegian setting. J Rehabil Med 43(6):534–542PubMedCrossRef
576.
Masiero S et al (2011) Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy: a randomized controlled trial. J Rheumatol 38(7):1335–1342PubMedCrossRef
577.
Van Tubergen A et al (2002) Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 47(5):459–467PubMedCrossRef
578.
Mau W, Muller A (2008) Rehabilitation and outpatient physiotherapy in rheumatic disease patients. Results of cross-sectional studies of patients with rheumatoid arthritis or ankylosing spondylitis and rheumatologists. Z Rheumatol 67(7):542–553PubMedCrossRef
579.
Boonen A et al (2010) ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health. Ann Rheum Dis 69(1):102–107PubMedCrossRef
580.
Boonen A et al (2009) Aspects relevant for functioning in patients with ankylosing spondylitis according to the health professionals: a Delphi study with the ICF as reference. Rheumatol (oxford) 48(8):997–1002CrossRef
581.
van Echteld I et al (2006) Identification of the most common problems by patients with ankylosing spondylitis using the international classification of functioning, disability and health. J Rheumatol 33(12):2475–2483PubMed
582.
Ward MM (1999) Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 12(4):247–255PubMedCrossRef
583.
Boonen A et al (2009) Which aspects of functioning are relevant for patients with ankylosing spondylitis: results of focus group interviews. J Rheumatol 36(11):2501–2511PubMedCrossRef
584.
Sigl T et al (2005) ICF based comparison of disease specific instruments measuring physical functional ability in ankylosing spondylitis. Ann Rheum Dis 64(11):1576–1581PubMedPubMedCentralCrossRef
585.
Gordeev VS et al (2010) Role of contextual factors in health-related quality of life in ankylosing spondylitis. Ann Rheum Dis 69(1):108–112PubMedCrossRef
586.
van Genderen S et al (2016) Social role participation in patients with Ankylosing Spondylitis: a cross-sectional comparison with population controls. Arthritis Care Res (hoboken) 68(12):1899–1905CrossRef
587.
Zink A, Mau W, Schneider M (2001) Epidemiologische und sozialmedizinische Aspekte entzündlich-rheumatischer Systemerkrankungen. Internist (Berl) 42(2):211–222CrossRef
588.
Ward MM, Kuzis S (2001) Risk factors for work disability in patients with ankylosing spondylitis. J Rheumatol 28(2):315–321PubMed
589.
Cakar E et al (2009) Work disability in ankylosing spondylitis: differences among working and work-disabled patients. Clin Rheumatol 28(11):1309–1314PubMedCrossRef
590.
Boonen A et al (2002) Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 61(5):429–437PubMedPubMedCentralCrossRef
591.
Boonen A et al (2001) Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 60(4):353–358PubMedPubMedCentralCrossRef
592.
Castillo-Ortiz JD et al (2016) Work outcome in patients with Ankylosing Spondylitis: results from a 12-year followup of an international study. Arthritis Care Res (hoboken) 68(4):544–552CrossRef
593.
Bönisch A et al (2005) Evaluation eines Schulungsprogramms für Patienten mit Spondylitis ankylosans. In: Pertermann F (Hrsg) Prädiktion, Verfahrensoptimierung und Kosten in der medizinischen Rehabilitation. S Roderer, Regensburg, S 51–102
594.
Krauth C et al (2005) Gesundheitsökonomische Evaluation eines Patientenschulungsprogramms Spondylitis ankylosans in der stationären Rehabilitation. In: Petermann F (Hrsg) Prädiktion, Verfahrensoptimierung und Kosten in der medizinischen Rehabilitation. S Roderer, Regensburg, S 103–143
595.
Mau W, Ehlebracht-Konig I (2013) Rehabilitation in axial spondyloarthritides. Rehabilitation (Stuttg) 52(1):51–62CrossRef
596.
Rodriguez-Lozano C et al (2013) Outcome of an education and home-based exercise programme for patients with ankylosing spondylitis: a nationwide randomized study. Clin Exp Rheumatol 31(5):739–748PubMed
597.
Mattey DL et al (2011) Relationship between smoking and patient-reported measures of disease outcome in ankylosing spondylitis. J Rheumatol 38(12):2608–2615PubMedCrossRef
598.
Zhao S et al (2017) Increasing smoking intensity is associated with increased disease activity in axial spondyloarthritis. Rheumatol Int 37(2):239–244PubMedCrossRef
599.
Ward MM et al (2009) Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. Arthritis Rheum 61(7):859–866PubMedPubMedCentralCrossRef
600.
Dougados M et al (2011) The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients. Joint Bone Spine 78(6):598–603PubMedCrossRef
601.
Chung HY et al (2012) Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. Ann Rheum Dis 71(6):809–816PubMedCrossRef
602.
Feldtkeller E (2002) Do patient self-help organizations help? Best Pract Res Clin Rheumatol 16(4):667–673PubMedCrossRef
Metadaten
Titel
Langfassung zur S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen, Update 2019
Evidenzbasierte Leitlinie der Deutschen Gesellschaft für Rheumatologie (DGRh) und der beteiligten medizinisch-wissenschaftlichen Fachgesellschaften und weiterer Organisationen*
verfasst von
PD Dr. med. U. Kiltz
Prof. Dr. med. J. Braun
Prof. Dr. med. A. Becker
Prof. Dr. med. J.-F. Chenot
PD Dr. med. M. Dreimann
L. Hammel
Prof. Dr. med. A. Heiligenhaus
PD Dr. med. K.‑G. Hermann
Prof. Dr. med. Dipl. Phys. R. Klett
PD Dr. med. D. Krause
Prof. Dr. med. K.‑F. Kreitner
Prof. Dr. med. U. Lange
A. Lauterbach
Prof. Dr. med. W. Mau
Prof. Dr. med. R. Mössner
Dr. med. U. Oberschelp
Dr. med. S. Philipp
Prof. Dr. med. U. Pleyer
Prof. Dr. med. M. Rudwaleit
Dr. med. E. Schneider
Prof. Dr. med. T. L. Schulte
Prof. Dr. med. em. J. Sieper
Prof. Dr. med. A. Stallmach
Prof. Dr. med. B. Swoboda
Prof. Dr. med. M. Winking
DGRh
DEGAM
DWG
DVMB
DOG
DRG
DGMM
DGPMR/DGRW
Physio Deutschland
DDG
DGOOC
DGIM
DGOOC/DGORh
DGNC
Publikationsdatum
01.12.2019
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Rheumatologie / Ausgabe Sonderheft 1/2019
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI
https://doi.org/10.1007/s00393-019-0670-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Parodontalbehandlung verbessert Prognose bei Katheterablation

18.04.2024 | Arterielle Hypertonie | Nachrichten

Antihypertensiva schützen auch alte Menschen noch vor Demenz

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

17.04.2024 | DGIM 2024 | Nachrichten

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise